Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1 (ITHER)
Sponsor: Centre Hospitalier Universitaire de Besancon
This NA trial investigates Cancer and is currently completed. Centre Hospitalier Universitaire de Besancon leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Mar 2026 — Present [monthly]
Completed NA
Status: Unknown → Completed
-
Sep 2025 — Mar 2026 [monthly]
Unknown NA
-
Sep 2024 — Sep 2025 [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Aug 2023 — Jul 2024 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
▶ Show 6 earlier versions
-
Sep 2021 — Aug 2023 [monthly]
Recruiting NA
Status: Unknown Status → Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
Jan 2019 — Jan 2021 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Jan 2019 [monthly]
Recruiting NA
-
Feb 2017 — Jun 2018 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting NA
First recorded
Aug 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Hospitalier Universitaire de Besancon
For direct contact, visit the study record on ClinicalTrials.gov .